Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

Executive Summary

The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations

Related Content

Orange Book patent listings
Schering Sales Force Recruitment Is 80% Complete; Morale Remains High
Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
FDA Developing Brand/Generic Labeling “Carve Out” Notification Process
Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority
Generic Ribavirin Dosing Concerns Can Be Addressed In MedGuide – Geneva
Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
Schering Rebetol Costs $1,650 Per Month, 3% Less Than Combo Rebetron
Bristol Seeking Two NDAs For UFT Combos In Response To Rebetron Debate



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts